**Table S3: Characteristics of Subjects with Natalizumab-associated PML Who Were Analyzed for CSF Cytokine Levels**

|  |  |  |  |
| --- | --- | --- | --- |
| Subject | CSF VL timepoint 1 | CSF VL timepoint 2 | time between samples |
| PML-1 | 21736 | 1070 | 2 months |
| PML-2 | 8925 | 613\* | 2 months\* |
| PML-3 | 1081 | no sample | no 2nd sample |
| PML-4 | 2275 | undetected | 4 years |
| PML-5 | 3879 | 82 | 3 months |
| PML-6 | 215 | 26 | 5 months |
| PML-7 | 96436 | 1114 | 5 months |
| PML-8 | 2374 | undetected | 7 months |
| PML-9 | 155 | undetected | 8 months |
| PML-10 | 51 | undetected | 4 months |

\*CSF timepoint 2 sample for subject PML-2 was not available at time of cytokine testing, and was not included in CSF cytokine analysis.